UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 4 | April 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 9 Issue 2
February-2022
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2202451


Registration ID:
320677

Page Number

e399-e405

Share This Article


Jetir RMS

Title

DNA based Nanocarriers for Cancer treatment

Abstract

The study aimed to achieve enhanced targeted toxicity and cell-internalization of cisplatin-loaded deoxyribonucleic acid-nanothread (CPT-DNA-NT), mediate by scavenger receptors into Hel cells. DNA-NT was developed with stiff-topology utilizing circular-scaffold to encapsulate CPT. Atomic force analysis (AFM) characterization of the DNA-NT showed uniformity among the structure with a diameter of 50–150 nm and length of 300–600 nm. The winning fabrication of the DNA-NT was confirmed through native-polyacrylamide gel activity analysis, as large the molecular-weight (polymeric) DNA-NT did not split into constituting strands beneath applied current and voltage. The results of cell viability confirmed that blank DNA-NT had the tiniest quantity toxicity at the most effective concentration (512 nM) with a viability of ninety 2 as proof of its biocompatibility for drug delivery. MTT assay showed superior toxicity of CPT-DNA-NT than that of the free CPT because of the depot unleash of CPT once DNA-NT incorporation. The DNA-NT exhibited targeted cell internalizations with the controlled living thing unleash of CPT (from DNA-NT), as illustrated in confocal photos. Therefore, in vitro toxicity assessment through flow cytometry showed enhanced programmed necrobiosis (72.7%) with CPT-DNA-NT (compared to free CPT; sixty four.4%). CPT-DNA-NT, being poly-anionic, showed enhanced endocytosis via scavenger receptors

Key Words

DNA, nanostructures, Self-assembly Nanocarriers Drug delivery, in vivo cancer treatments

Cite This Article

"DNA based Nanocarriers for Cancer treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 2, page no.e399-e405, February-2022, Available :http://www.jetir.org/papers/JETIR2202451.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"DNA based Nanocarriers for Cancer treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 2, page no. ppe399-e405, February-2022, Available at : http://www.jetir.org/papers/JETIR2202451.pdf

Publication Details

Published Paper ID: JETIR2202451
Registration ID: 320677
Published In: Volume 9 | Issue 2 | Year February-2022
DOI (Digital Object Identifier):
Page No: e399-e405
Country: Aurangabad, Maharashtra, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000358

Print This Page

Current Call For Paper

Jetir RMS